Pacira BioSciences, Inc. (PCRX)

Pacira BioSciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	70.47	41.96	15.91	41.98	145.52	-11.02
Depreciation & Amortization	74.4	75.57	91.5	28.55	19.91	19.58
Share-Based Compensation	49.06	47.9	48.09	42.25	39.92	33.65
Other Operating Activities	-9.3	-10.78	-10.23	12.94	-128.32	28.31
Operating Cash Flow	184.62	154.65	145.27	125.72	77.03	70.52
Operating Cash Flow Growth	38.16%	6.45%	15.56%	63.20%	9.23%	44.30%
Capital Expenditures	-11.43	-15.16	-30.08	-45.87	-37.8	-10.16
Acquisitions	0	0	-32	-424.04	0	-117.69
Change in Investments	7.26	92.7	-163.11	449.12	-239.81	-0.64
Investing Cash Flow	-4.17	77.54	-225.19	-20.79	-277.61	-128.49
Share Issuance / Repurchase	4.42	4.75	27.34	26.66	102.47	10.87
Debt Issued / Paid	-36.25	-187.68	-428.87	359.2	125.43	-0.34
Other Financing Activities	-0.11	-0.11	-	-5.17	-5.59	-6.86
Financing Cash Flow	-31.94	-183.03	-401.53	380.69	222.3	3.67
Net Cash Flow	148.51	49.16	-481.44	485.62	21.73	-54.3
Free Cash Flow	173.19	139.49	115.2	79.85	39.23	60.36
Free Cash Flow Growth	65.49%	21.09%	44.27%	103.54%	-35.01%	75.69%
Free Cash Flow Margin	25.40%	20.67%	17.28%	14.75%	9.13%	14.34%
Free Cash Flow Per Share	3.73	3.02	2.53	1.80	0.92	1.45

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).